Market Overview:
The global noninvasive cancer diagnostics market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The market growth is attributed to the increasing incidence of cancer, technological advancements in noninvasive cancer diagnostics, and rising demand for early diagnosis and treatment of cancer. Based on type, the global noninvasive cancer diagnostics market is segmented into clinical chemistry, immunochemistry/immunoassay, molecular diagnostics, and others. Clinical chemistry dominates the global noninvasive cancer diagnostics market due to its high usage in hospitals and clinics for routine blood tests. Immunochemistry/immunoassay is expected to be the fastest-growing segment during the forecast period owing to its growing use in point-of-care testing (POC) settings for detection of various types of cancers. Based on application, the global noninvasive cancer diagnostics market is segmented into solid tumors, blood cancers (leukemia & lymphoma), lung cancers (adenocarcinoma & squamous cell carcinoma), breast cancers (ductal carcinoma & lobular carcinoma), and others.
Product Definition:
Noninvasive cancer diagnostics are tests that can be used to detect cancer without having to perform surgery. These tests can include blood tests, imaging scans, and biopsies. The importance of noninvasive cancer diagnostics is that they can help to identify cancers at an early stage when they are more likely to be treated successfully.
Clinical Chemistry:
Clinical chemistry is the branch of medical science that deals with the study of body functions and diseases by analyzing chemical composition, physical properties, and disease diagnosis through various tests. Clinical chemistry market is expected to witness lucrative growth over the forecast period owing to increasing demand for noninvasive diagnostic tools in oncology coupled with technological advancements such as high performance liquid chromatography (HPLC) systems & mass spectrometers.
Immunochemistry/Immunoassay:
Immunoassay is a technique that involves the use of antibodies and their specific recognition properties for cancer diagnosis. Immunoassay helps in the detection of disease by differentiating between healthy cells and cancer cells. It also helps in differentiating between malignant tumors and benign tumors, which are mostly used for screening, monitoring, diagnosing as well as treatment planning.
Application Insights:
The solid tumor segment dominated the global market in 2017. This can be attributed to increasing prevalence of cancer and growing demand for noninvasive diagnostic solutions for early detection. For instance, as per the American Cancer Society, in 2018, around 1 in 8 women are estimated to develop invasive breast cancer during their lifetime. Thus, increase in incidence of such diseases coupled with rising awareness is expected to drive growth over the forecast period.
Noninvasive blood tests are used for diagnosis of blood cancers such as myelodysplastic syndrome and acute lymphoblastic leukemia (ALL). These tests identify abnormalities present in the patient¢â‚¬â„¢s blood sample which may not be visible using conventional methods including microscopy or biopsies taken from affected areas of skin. Hence, they provide more sensitive and specific means for diagnosis compared to conventional methods that have been used until now.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, high adoption rate of technologically advanced products and increasing government initiatives for cancer screening programs. For instance, as per a recent study published by National Cancer Institute (NCI), from 2014 to 2016, around 2 million people in U.S., aged 50 to 74 years had participated in one or more cancer screening programs conducted by their respective state health departments (SDs).
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising disposable income levels and growing target population base especially in countries like China & India that are adopting western culture and lifestyle resulting into an increase incidence rates of various cancers such as breast & prostate cancers along with blood diseases such as leukemia & lymphoma at a faster pace compared with other developing nations across this region is also attributive towards this trend.
Growth Factors:
- Increasing incidence of cancer: The global incidence of cancer is increasing at an alarming rate. This is primarily due to the aging population and the rising prevalence of lifestyle-related cancers. According to the World Health Organization, there were 14 million new cases of cancer in 2012, and this number is expected to rise to 21 million by 2030. This presents a huge opportunity for noninvasive cancer diagnostics market players.
- Advances in technology: Technological advances are paving the way for novel noninvasive diagnostic techniques that are more accurate and sensitive than traditional methods. For instance, next-generation sequencing (NGS) technology can be used to detect genetic mutations associated with various types of cancers. This is helping researchers develop better diagnostic tests that can provide more accurate results in a shorter time frame.
- Growing demand for personalized medicine: There is growing demand for personalized medicine across all industries, and healthcare is no exception. Patients want treatments that are tailored specifically for them, based on their individual characteristics such as age, gender, genetics, etcetera . Noninvasive cancer diagnostics allow clinicians to tailor treatment plans according to each patient’s unique needs , which helps improve outcomes .
Scope Of The Report
Report Attributes
Report Details
Report Title
Noninvasive Cancer Diagnostics Market Research Report
By Type
Clinical Chemistry, Immunochemistry/Immunoassay, Molecular Diagnostics, Others
By Application
Solid Tumors, Blood Cancer, Lung Cancer, Breast Cancer, Others
By Companies
Precision Therapeutics, Inc. (U.S.), A&G Pharmaceutical, Inc. (U.S.), Affymetrix Inc. (U.S.), AVIVA Biosciences Corporation (U.S.), BIOVIEW Inc. (U.S.), Laboratory Corporation of America Holdings (LabCorp) (U.S.), Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.), Digene Corporation (U.S.), Gen-Probe Incorporated (U.S.), IVDiagnostics, Inc. (U.S.)
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
174
Number of Tables & Figures
122
Customization Available
Yes, the report can be customized as per your need.
Global Noninvasive Cancer Diagnostics Market Report Segments:
The global Noninvasive Cancer Diagnostics market is segmented on the basis of:
Types
Clinical Chemistry, Immunochemistry/Immunoassay, Molecular Diagnostics, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Solid Tumors, Blood Cancer, Lung Cancer, Breast Cancer, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Precision Therapeutics, Inc. (U.S.)
- A&G Pharmaceutical, Inc. (U.S.)
- Affymetrix Inc. (U.S.)
- AVIVA Biosciences Corporation (U.S.)
- BIOVIEW Inc. (U.S.)
- Laboratory Corporation of America Holdings (LabCorp) (U.S.)
- Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.)
- Digene Corporation (U.S.)
- Gen-Probe Incorporated (U.S.)
- IVDiagnostics, Inc. (U.S.)
Highlights of The Noninvasive Cancer Diagnostics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Clinical Chemistry
- Immunochemistry/Immunoassay
- Molecular Diagnostics
- Others
- By Application:
- Solid Tumors
- Blood Cancer
- Lung Cancer
- Breast Cancer
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Noninvasive Cancer Diagnostics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Noninvasive cancer diagnostics is a term used to describe any diagnostic tests that do not involve surgery. These tests can be used to detect cancer in the early stages, when it is more treatable.
Some of the major players in the noninvasive cancer diagnostics market are Precision Therapeutics, Inc. (U.S.), A&G Pharmaceutical, Inc. (U.S.), Affymetrix Inc. (U.S.), AVIVA Biosciences Corporation (U.S.), BIOVIEW Inc. (U.S.), Laboratory Corporation of America Holdings (LabCorp) (U.S.), Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.), Digene Corporation (U.S.), Gen-Probe Incorporated (U.S.), IVDiagnostics, Inc. (U.S.).
The noninvasive cancer diagnostics market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Noninvasive Cancer Diagnostics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Noninvasive Cancer Diagnostics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Noninvasive Cancer Diagnostics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Noninvasive Cancer Diagnostics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Noninvasive Cancer Diagnostics Market Size & Forecast, 2018-2028
4.5.1 Noninvasive Cancer Diagnostics Market Size and Y-o-Y Growth
4.5.2 Noninvasive Cancer Diagnostics Market Absolute $ Opportunity
Chapter 5 Global Noninvasive Cancer Diagnostics Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Noninvasive Cancer Diagnostics Market Size Forecast by Type
5.2.1 Clinical Chemistry
5.2.2 Immunochemistry/Immunoassay
5.2.3 Molecular Diagnostics
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Noninvasive Cancer Diagnostics Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Noninvasive Cancer Diagnostics Market Size Forecast by Applications
6.2.1 Solid Tumors
6.2.2 Blood Cancer
6.2.3 Lung Cancer
6.2.4 Breast Cancer
6.2.5 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Noninvasive Cancer Diagnostics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Noninvasive Cancer Diagnostics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Noninvasive Cancer Diagnostics Analysis and Forecast
9.1 Introduction
9.2 North America Noninvasive Cancer Diagnostics Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Noninvasive Cancer Diagnostics Market Size Forecast by Type
9.6.1 Clinical Chemistry
9.6.2 Immunochemistry/Immunoassay
9.6.3 Molecular Diagnostics
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Noninvasive Cancer Diagnostics Market Size Forecast by Applications
9.10.1 Solid Tumors
9.10.2 Blood Cancer
9.10.3 Lung Cancer
9.10.4 Breast Cancer
9.10.5 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Noninvasive Cancer Diagnostics Analysis and Forecast
10.1 Introduction
10.2 Europe Noninvasive Cancer Diagnostics Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Noninvasive Cancer Diagnostics Market Size Forecast by Type
10.6.1 Clinical Chemistry
10.6.2 Immunochemistry/Immunoassay
10.6.3 Molecular Diagnostics
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Noninvasive Cancer Diagnostics Market Size Forecast by Applications
10.10.1 Solid Tumors
10.10.2 Blood Cancer
10.10.3 Lung Cancer
10.10.4 Breast Cancer
10.10.5 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Noninvasive Cancer Diagnostics Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Noninvasive Cancer Diagnostics Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Noninvasive Cancer Diagnostics Market Size Forecast by Type
11.6.1 Clinical Chemistry
11.6.2 Immunochemistry/Immunoassay
11.6.3 Molecular Diagnostics
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Noninvasive Cancer Diagnostics Market Size Forecast by Applications
11.10.1 Solid Tumors
11.10.2 Blood Cancer
11.10.3 Lung Cancer
11.10.4 Breast Cancer
11.10.5 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Noninvasive Cancer Diagnostics Analysis and Forecast
12.1 Introduction
12.2 Latin America Noninvasive Cancer Diagnostics Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Noninvasive Cancer Diagnostics Market Size Forecast by Type
12.6.1 Clinical Chemistry
12.6.2 Immunochemistry/Immunoassay
12.6.3 Molecular Diagnostics
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Noninvasive Cancer Diagnostics Market Size Forecast by Applications
12.10.1 Solid Tumors
12.10.2 Blood Cancer
12.10.3 Lung Cancer
12.10.4 Breast Cancer
12.10.5 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Noninvasive Cancer Diagnostics Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Noninvasive Cancer Diagnostics Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Noninvasive Cancer Diagnostics Market Size Forecast by Type
13.6.1 Clinical Chemistry
13.6.2 Immunochemistry/Immunoassay
13.6.3 Molecular Diagnostics
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Noninvasive Cancer Diagnostics Market Size Forecast by Applications
13.10.1 Solid Tumors
13.10.2 Blood Cancer
13.10.3 Lung Cancer
13.10.4 Breast Cancer
13.10.5 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Noninvasive Cancer Diagnostics Market: Competitive Dashboard
14.2 Global Noninvasive Cancer Diagnostics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Precision Therapeutics, Inc. (U.S.)
14.3.2 A&G Pharmaceutical, Inc. (U.S.)
14.3.3 Affymetrix Inc. (U.S.)
14.3.4 AVIVA Biosciences Corporation (U.S.)
14.3.5 BIOVIEW Inc. (U.S.)
14.3.6 Laboratory Corporation of America Holdings (LabCorp) (U.S.)
14.3.7 Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.)
14.3.8 Digene Corporation (U.S.)
14.3.9 Gen-Probe Incorporated (U.S.)
14.3.10 IVDiagnostics, Inc. (U.S.)
